These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1100 related articles for article (PubMed ID: 29552012)

  • 21. Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment.
    Pramanik A; Bhattacharyya S
    Life Sci; 2022 Sep; 305():120755. PubMed ID: 35780842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
    Krishnamoorthy M; Gerhardt L; Maleki Vareki S
    Cells; 2021 May; 10(5):. PubMed ID: 34065010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innate myeloid cells in the tumor microenvironment.
    Duhan V; Smyth MJ
    Curr Opin Immunol; 2021 Apr; 69():18-28. PubMed ID: 33588308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural Killer Cells Reprogram Myeloid-Derived Suppressor Cells to Induce TNF-α Release via NKG2D-Ligand Interaction after Cryo-Thermal Therapy.
    You J; Wang S; Zhu Y; Zhang Z; Wang J; Lou Y; Yao Y; Hao Y; Liu P
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Critical immunosuppressive effect of MDSC‑derived exosomes in the tumor microenvironment.
    Rashid MH; Borin TF; Ara R; Piranlioglu R; Achyut BR; Korkaya H; Liu Y; Arbab AS
    Oncol Rep; 2021 Mar; 45(3):1171-1181. PubMed ID: 33469683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer.
    Vetsika EK; Koukos A; Kotsakis A
    Cells; 2019 Dec; 8(12):. PubMed ID: 31847487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT.
    Tumino N; Di Pace AL; Besi F; Quatrini L; Vacca P; Moretta L
    Front Immunol; 2021; 12():638841. PubMed ID: 33679798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression.
    Xing Y; Ruan G; Ni H; Qin H; Chen S; Gu X; Shang J; Zhou Y; Tao X; Zheng L
    Front Immunol; 2021; 12():624725. PubMed ID: 34084160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?
    Wu Y; Chen D; Gao Y; Xu Q; Zhou Y; Ni Z; Na M
    Hum Cell; 2024 Jul; 37(4):931-943. PubMed ID: 38814516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.
    Zhang J; Hodges A; Chen SH; Pan PY
    Cell Immunol; 2021 Apr; 362():104300. PubMed ID: 33582607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer.
    Li L; Li M; Jia Q
    Pathol Res Pract; 2023 Aug; 248():154711. PubMed ID: 37494802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.
    Chen Z; Yuan R; Hu S; Yuan W; Sun Z
    Front Immunol; 2022; 13():817942. PubMed ID: 35154134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Myeloid-Derived Suppressor Cells in Cancer.
    Anani W; Shurin MR
    Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloid derived suppressor cells and the release of micro-metastases from dormancy.
    Khadge S; Cole K; Talmadge JE
    Clin Exp Metastasis; 2021 Jun; 38(3):279-293. PubMed ID: 34014424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of myeloid-derived suppressor cells in metastasis.
    Cole K; Pravoverov K; Talmadge JE
    Cancer Metastasis Rev; 2021 Jun; 40(2):391-411. PubMed ID: 33411082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy of targeting MDSCs in tumor microenvironment.
    Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
    Front Immunol; 2022; 13():990463. PubMed ID: 36131911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.
    Adeshakin AO; Adeshakin FO; Yan D; Wan X
    Front Immunol; 2022; 13():781660. PubMed ID: 35140716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homocitrullination of lysine residues mediated by myeloid-derived suppressor cells in the tumor environment is a target for cancer immunotherapy.
    Cook KW; Xue W; Symonds P; Daniels I; Gijon M; Boocock D; Coveney C; Miles AK; Shah S; Atabani S; Choudhury RH; Vaghela P; Weston D; Metheringham RL; Brentville VA; Durrant LG
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.